• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » San Antonio's cancer genomics partnership launches

San Antonio's cancer genomics partnership launches

November 4, 2015
CenterWatch Staff

The San Antonio 1000 Cancer Genomes Project (SA1kCGP), Shanghai-based WuXi NextCODE and South Texas Accelerated Research Therapeutics (START) have partnered to enable San Antonio’s pioneering citywide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for the resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.

START, which operates a phase I medical oncology program through clinical sites in the U.S., China and Spain, has contracted with WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, to sequence and interpret the samples. WuXi NextCODE will utilize its CLIA sequence laboratory and its HIPAA-compliant NextCLOUD secondary analysis and storage solution, powered by DNAnexus. START is connecting the “delta file” to anonymized patient electronic clinical records using the Medidata Rave system, and will make it available to qualified researchers and clinicians via the cloud.

“Our three organizations share the mission of using our unique capabilities and assets to create better medicine for patients everywhere,” said Dr. Anthony Tolcher, director of clinical research at START. “WuXi NextCODE was the logical partner in genomics. They bring to this project the same expertise they are deploying in large-scale precision oncology initiatives from Genomics England to Qatar, backed by the renowned clinical development capabilities of WuXi AppTec.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing